Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Arcutis Biotherapeutics, Inc. keeps $6 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arcutis Biotherapeutics’ EPS trailed consensus even as revenue came in line, as the company posted the third fiscal quarter of 2026 results on November 4, 2026 with revenue up 45.1% year over year to about $143.9 million (up from roughly $99.2 million a year ago). EPS of $0.06 trailed the $0.18 estimate (-66.7%), while revenue of $143.9 million was in line with the $142.6 million estimate (+0.9%). Profitability stayed high, with gross profit of about $131.5 million translating to a gross margin near 91%, and operating income of roughly $9.4 million for an operating margin around 7%. Net income rose 18.8% from a year ago to about $8.8 million (versus roughly $7.4 million a year ago), and the quarter generated operating cash flow of about $18.9 million. For the next period, consensus calls for EPS of $0.22 on revenue of $160.7 million.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. develops and markets therapies for skin-related diseases and operates as a biotechnology company listed on the NASDAQ under ARQT. In FY2025, the company generated $376.1 million in revenue. Formerly known as Arcutis, Inc., it focuses on dermatology products and pipeline programs built around inflammatory skin conditions.
Today's Snapshot
The day ended with ARQT 1% higher at 27.61, outperforming a weaker sector. Volume was about a third of its usual level.
Trading Volume
Below 10d avg (2.5M)
835.3K
vs S&P 500 Today
Outperforming Market
+1.28%
Updated: November 18, 2026 at 21:30 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$26.51 - $28.51Sell
- RSI (14)46.65Neutral
- Stochastic %K (14, 3, 3)22.29Neutral
- MACD Level (12, 26)-0.32Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.